Trial
NCT02987998
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Nathan Pennell, MD, PhD
Collaborators
—
Condition
Stage IIIA Non-Small Cell Lung Cancer
Intervention
Cisplatin
Why stopped
higher than expected rate of toxicity \& unrealistic timeline to complete trial under company's proposed plan to reopen
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-19